Skip to content
← All treatment topics

TREATMENT READING

Gastrointestinal Neuroendocrine Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

42 sections
  1. Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors
  2. Surgery
  3. Somatostatin Analogues
  4. Interferons
  5. Treatment of Hepatic Metastases
  6. Radionuclides
  7. Management of Neuroendocrine Tumor–Related Fibrosis
  8. Symptomatic Therapy
  9. Molecular-Targeted Therapies
  10. General Therapeutic Approaches
  11. Treatment of Gastric Neuroendocrine Tumors
  12. Treatment of Duodenal Neuroendocrine Tumors
  13. Treatment of Jejunal and Ileal Neuroendocrine Tumors
  14. Treatment of Appendiceal Neuroendocrine Tumors
  15. Treatment of Colonic Neuroendocrine Tumors
  16. Treatment of Rectal Neuroendocrine Tumors
  17. Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors
  18. Treatment of Recurrent Gastrointestinal Neuroendocrine Tumors
  19. Certain factors affect prognosis (chance of recovery) and treatment options.
  20. The plan for cancer treatment depends on where the neuroendocrine tumor is found and whether it can be removed by surgery.
  21. Treatment Option Overview
  22. Key Points
  23. There are different types of treatment for patients with gastrointestinal neuroendocrine tumors.
  24. The following types of treatment are used:
  25. Surgery
  26. Radiation therapy
  27. Chemotherapy
  28. Hormone therapy
  29. Treatment for carcinoid syndrome may also be needed.
  30. New types of treatment are being tested in clinical trials.
  31. Targeted therapy
  32. Treatment for gastrointestinal neuroendocrine tumors may cause side effects.
  33. Patients may want to think about taking part in a clinical trial.
  34. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  35. Follow-up care may be needed.
  36. Treatment of Neuroendocrine Tumors in the Stomach
  37. Treatment of Neuroendocrine Tumors in the Small Intestine
  38. Treatment of Neuroendocrine Tumors in the Appendix
  39. Treatment of Neuroendocrine Tumors in the Colon
  40. Treatment of Neuroendocrine Tumors in the Rectum
  41. Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors
  42. Treatment of Recurrent Gastrointestinal Neuroendocrine Tumors

Health professional

Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Treatment options for patients with gastrointestinal neuroendocrine (carcinoid) tumors include:

Surgery.

Somatostatin analogues.

Interferons.

Treatment of hepatic metastases.

Radionuclides.

Management of neuroendocrine tumor–related fibrosis.

Symptomatic therapy.

Molecular-targeted therapies (under clinical evaluation).

Therapies for symptomatic relief.

Antifibrotic therapies (under clinical evaluation).[1]

Sources: 1

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Surgery

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The only potentially curative therapy for gastrointestinal neuroendocrine tumors, which may be possible in as many as 20% of patients, is resection of the primary tumor and local lymph nodes.[2-4] Endoscopic surgery may be suitable for some tumors depending on the location, number, size, and degree of malignancy.[4] Resection of nonhepatic tumor primaries is associated with increased median survival ranging from 69 to 139 months.[5,6] However, the extent of resection depends on the site of origin of a given tumor, the involvement of surrounding structures, and the extent of metastases.[1]

Sources: 2 · 4 · 4 · 5 · 6 · 1

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Somatostatin Analogues

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The development of long-acting and depot formulations of somatostatin analogues has been important in the amelioration of symptoms of carcinoid syndrome. The result has been a substantial improvement in quality of life with relatively mild adverse effects.[1,7] The inhibitory effects of somatostatin on neurotransmission, motor and cognitive functions, smooth muscle contractility, glandular and exocrine secretions, intestinal motility, and absorption of nutrients and ions are mediated by cyclic adenosine monophosphate inhibition.[8,9] Experimentally, somatostatin has been shown to have a cytostatic effect on tumor cells. This effect involves hyperphosphorylation of the retinoblastoma gene product and G1 cell cycle arrest, in addition to somatostatin receptor (SSTR) subtype 3 [sst(3)]-mediated (and to a lesser extent, SSTR subtype [sst(2)]-mediated) apoptosis.[10-12] Somatostatin also appears to have some antiangiogenic properties.[1] However, only a small number of patients treated with somatostatin analogue therapy experience partial tumor regression.[1,4]

Sources: 1 · 7 · 8 · 9 · 10 · 12 · 1 · 1 · 4

Available somatostatin analogues display high affinity for sst(2) and SSTR subtype 5, low affinity for SSTR subtype 1 and SSTR subtype 4, and medium affinity for sst(3). For more information, see the Somatostatin receptor scintigraphy section. Octreotide, a short-acting somatostatin analogue and the first biotherapeutic agent used in the management of neuroendocrine tumors, exhibits beneficial effects that are limited to symptom relief, with about 70% of patients experiencing resolution of diarrhea or flushing. [1,4]

Sources: Somatostatin receptor scintigraphy · 1 · 4

In the treatment of neuroendocrine tumors, lanreotide, a long-acting somatostatin analogue administered every 10 to 14 days, has an efficacy similar to that of octreotide and an agreeable formulation for patient use.[13] The effects of lanreotide on symptom relief are comparable to those of octreotide, with 75% to 80% of patients reporting decreased diarrhea and flushing; however, there appears to be little improvement in tumor responses over shorter-acting octreotide.[1] Depot formulations include long-acting repeatable (LAR) octreotide and a slow-release depot preparation of lanreotide. One study comparing subcutaneous short-acting octreotide with monthly LAR octreotide reported an increased median survival from the time of metastatic disease diagnosis (143 months vs. 229 months in favor of the LAR form), representing a 66% lower risk of death among patients treated with the LAR formulation.[14] A randomized controlled study in patients with metastatic midgut neuroendocrine tumors showed improved time to tumor progression with monthly LAR octreotide compared with placebo. For more information, see the Treatment of Jejunal and Ileal Neuroendocrine Tumors section.

Sources: 13 · 1 · 14 · Treatment of Jejunal and Ileal Neuroendocrine Tumors

The typical duration of treatment with somatostatin analogues is approximately 12 months because of the development of tachyphylaxis (reported less frequently with long-acting formulations) and/or disease progression.[15-17] In the management of carcinoid crises, intravenous somatostatin analogues are effective; crises are usually precipitated by anesthesia, surgical interventions, or radiologic interventions.[18] Adverse effects of somatostatin analogue administration include:[19,20]

Sources: 15 · 17 · 18 · 19 · 20

Nausea.

Cramping.

Loose stools.

Steatorrhea.

Cardiac conduction abnormalities and arrhythmias.

Endocrine disturbances (e.g., hypothyroidism, hypoglycemia, or, more commonly, hyperglycemia).

Gastric atony (rarely).

Biliary sludge and cholelithiasis occur in as many as 50% of the patients, but few patients (1%–3%) develop acute symptoms requiring cholecystectomy.[21]

Sources: 21

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Interferons

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The most researched interferon in the treatment of neuroendocrine tumors is interferon alfa (IFN alfa). Comparable to somatostatin analogues, the most pronounced effects of IFN alfa are inhibition of disease progression and symptom relief, with approximately 75% of patients reporting the resolution of diarrhea or flushing.[1] IFN alfa, like other IFNs studied in the treatment of neuroendocrine tumors (e.g., IFN gamma and human leukocyte interferon), has substantial adverse effects, including alopecia, anorexia, fatigue, weight loss, fever, a flu-like syndrome, and myelosuppression. However, IFN alfa may show greater antitumor activity than somatostatin analogues.[13] Both single-agent and multiagent chemotherapeutics appear to have little role in the management of these essentially chemoresistant tumors; no protocol has shown objective tumor response rates greater than 15%.[1]

Sources: 1 · 13 · 1

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Treatment of Hepatic Metastases

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The management of hepatic metastases may include surgical resection; hepatic artery embolization; cryoablation and radiofrequency ablation (RFA); and orthotopic liver transplant.[1] In one large review of 120 patients with neuroendocrine tumors, a biochemical response rate of 96% and a 5-year survival rate of 61% were reported for patients whose hepatic metastases were resected surgically.[22] The 5-year survival rate without surgical therapy was approximately 30%.[4] For hepatic artery embolization, the most frequently used single agent is gelatin powder. In more than 60 patients with neuroendocrine tumors, the use of gelatin powder resulted in 34% and 42% of patients achieving biochemical and tumor-diminution responses, respectively.[23-25] Trials using transcatheter arterial occlusion with chemoembolization have also been performed, with the most thoroughly researched combination involving hepatic artery ligation with gelatin foam and doxorubicin (4 trials and 66 patients), resulting in biochemical responses in 71% of patients and tumor regression in approximately 50% of patients.[1] However, the duration of response can be short lived after embolization, and embolization may be associated with adverse effects that range from transient symptoms (e.g., pain, nausea, fever, and fatigue), which occur in 30% to 70% of patients, to liver enzyme abnormalities, which occur in as many as 100% of patients (i.e., transaminitis and postembolization syndrome), to florid and potentially lethal carcinoid crisis with massive release of vasoactive substances.[4]

Sources: 1 · 22 · 4 · 23 · 25 · 1 · 4

In one prospective trial, 80 RFA sessions were performed in 63 patients with neuroendocrine hepatic metastases (including 36 carcinoids), and 92% of the patients reported at least partial symptom relief. In the same 63 patients, 70% had significant or complete relief at 1 week postoperatively, with a perioperative morbidity of 5%; duration of symptom control was 11 ± 2.3 months, and median survival time was 3.9 years after the first RFA.[26] There are few trials of cryoablation of hepatic metastases, and the results of liver transplant for metastatic disease are disappointing, reflecting the typically advanced disease states of transplant recipients.[1]

Sources: 26 · 1

Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Radionuclides

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The four radionuclide conjugates most commonly used in the treatment of neuroendocrine tumors are iodine I 131-metaiodobenzylguanidine (131I-MIBG), indium In 111 (111In), yttrium Y 90, and lutetium Lu 177 (177Lu), with the latter three bound to a variety of somatostatin analogues. However, the median tumor response rate for the patients treated with 131I-MIBG is less than 5%, although the modality appears somewhat more effective in achieving biochemical stability (~50%) or tumor stability (~70%).[1] Although 111In-labeled somatostatin analogues are the most commonly studied radiopeptides to date, largely reflecting their availability, and with therapeutic benefits similar to 131I-MIBG, the most promising advance in radiopeptide therapeutics has been the development of 177Lu-octreotate, which emits both beta and gamma radiation.[1] In the largest patient series treated to date with lutetium-labeled somatostatin analogues (n = 131; 65 with gastrointestinal neuroendocrine tumors), remission rates were correlated positively with high pretherapy octreotide scintigraphy uptake and limited hepatic tumor load.[27] In patients with extensive liver involvement, median time to progression was shorter (26 months) compared with patients who had either stable disease or tumor regression (>36 months).

Sources: 1 · 1 · 27

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Management of Neuroendocrine Tumor–Related Fibrosis

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Bowel obstruction secondary to peritoneal fibrosis is the most common presenting symptom of small intestinal neuroendocrine tumors. Heart failure secondary to right-sided valvular fibrosis represents a serious extraintestinal manifestation of neuroendocrine tumor–related fibrosis. It occurs in 20% to 70% of patients with metastatic disease and it accounts for as much as 50% of neuroendocrine tumor mortality.[28,29] There is no effective pharmacological therapy for either clinical problem. In the instance of bowel obstruction, surgical lysis of the adhesions often is technically demanding because of the cocoon-like effects of extensive fibrosis stimulated by the various tumor-derived growth factors.[30] Valvular replacement usually is required to manage carcinoid heart disease.[1]

Sources: 28 · 29 · 30 · 1

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Symptomatic Therapy

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

In addition to the use of long-acting depot formulations of somatostatin analogues to ameliorate neuroendocrine tumor symptoms, supportive care of patients includes:

Advising them to avoid factors that induce flushing or bronchospastic episodes, including:

Advising them to avoid factors that induce flushing or bronchospastic episodes, including:

Ingestion of alcohol, certain cheeses, capsaicin-containing foods, and nuts.

Stressful situations.

Some kinds of physical activity.

Diarrhea may be treated with conventional antidiarrheal agents such as loperamide or diphenoxylate; more pronounced diarrhea may be treated with the 5-HT receptor subtype 2 antagonist cyproheptadine, which is effective in as many as 50% of patients and may also help alleviate anorexia or cachexia in patients with a malignant carcinoid syndrome.[1]

Sources: 1

Histamine 1 receptor blockade with fexofenadine, loratadine, terfenadine, or diphenhydramine may help treat skin rashes, particularly in histamine-secreting gastric neuroendocrine tumors.

Bronchospasm can be managed with theophylline or beta-2 adrenergic receptor agonists such as albuterol.[1]

Sources: 1

Carcinoid crisis is manifested by profound flushing, extreme blood pressure fluctuations, bronchoconstriction, dysrhythmias, and confusion or stupor lasting hours or days and may be provoked by induction of anesthesia or an invasive radiologic procedure.[18,31] This potentially fatal condition can occur after manipulation of tumor masses (including bedside palpation), administration of chemotherapy, or hepatic arterial embolization.[32] In contrast with the treatment of other causes of acute hypotension, the use of calcium and catecholamines should be avoided in carcinoid crisis because these agents provoke the release of bioactive tumor mediators that may perpetuate or worsen the situation. Plasma infusion and octreotide are used for hemodynamic support. For the most part, the use of somatostatin analogues has replaced other pharmacological maneuvers in the treatment of crises, and their use has been associated with increased survival rates. Prophylactic use of subcutaneous octreotide or the administration of a depot somatostatin analogue in a timely fashion before any procedures are undertaken is mandatory to prevent the development of a crisis.[1]

Sources: 18 · 31 · 32 · 1

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

Molecular-Targeted Therapies

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Various therapies targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor, and mammalian target of rapamycin (mTOR) are in development.[1,33] Therapeutic agents under investigation include the VEGF monoclonal antibody, bevacizumab and VEGF tyrosine kinase inhibitors, sunitinib, vatalanib, and sorafenib.

Sources: 1 · 33

Health professional · Treatment Option Overview for Gastrointestinal Neuroendocrine Tumors

General Therapeutic Approaches

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

As might be expected, therapeutic approaches to gastrointestinal neuroendocrine tumors vary according to anatomical location. In 2004, a consensus statement regarding the diagnosis and treatment of gastrointestinal neuroendocrine tumors was published on behalf of the European Neuroendocrine Tumor Society,[4] which details site-specific approaches to treatment.

Sources: 4

Health professional

Treatment of Gastric Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Type I gastric neuroendocrine (carcinoid) tumors smaller than 1 cm are indolent with minimal risk for invasion and can be removed with endoscopic mucosal resection.[1-3] Local surgical excision may be performed for rare larger or invasive tumors, but exceptional cases with large multifocal lesions may require gastric resection. Follow-up with yearly endoscopic surveillance and repeated gastroscopy with multiple gastric biopsies is required, and treatment with somatostatin analogues may prevent recurrence.[4]

Sources: 1 · 3 · 4

For type II neuroendocrine tumors, surgery is focused on removing the source of hypergastrinemia, typically by excision of duodenal gastrinomas in patients with multiple endocrine neoplasia type I via duodenotomy with resection of lymph node metastases.[5-7] Because of their generally benign course similar to type I tumors, type II tumors can usually be managed with endoscopic resection (particularly for tumors <1 cm), followed by close endoscopic surveillance.[1,3] Liberal surgical excision or gastric resection with regional lymphadenectomy is performed for larger and multifocal tumors or for those with deep wall invasion or angioinvasion.[3] In patients with multiple tumors, somatostatin analogue treatment may be used to reduce tumor growth, particularly if hypergastrinemia has not been reversed by surgery.[4]

Sources: 5 · 7 · 1 · 3 · 3 · 4

Sporadic type III gastric neuroendocrine tumors, which behave more aggressively than type I and type II tumors, are treated with gastric resection and regional lymphadenectomy.[3] Tumors larger than 2 cm or those with atypical histology or gastric wall invasion are most appropriately dealt with by gastrectomy or radical gastrectomy.[1,8,9] Most of these tumors are metastatic at the time of presentation.[8] The 5-year survival rate may approach 50%, but, in patients with distant metastases, it is only 10%.[10,11]

Sources: 3 · 1 · 8 · 9 · 8 · 10 · 11

Subtyping gastric neuroendocrine tumors is helpful in the prediction of malignant potential and long-term survival and as a guide to management.[12] Based on a combined population from 24 Swedish hospitals, one study of 65 patients with gastric neuroendocrine tumors (51 type I, 1 type II, 4 type III, and 9 poorly differentiated [designated as type IV in the study]), management varied according to tumor type. Among all of the patients, 3 received no specific treatment, 40 underwent endoscopic or surgical excision (in 10 cases combined with antrectomy), 7 underwent total gastrectomy, and 1 underwent proximal gastric resection. Radical tumor removal could not be performed in 2 of 4 patients with type III tumors and in 7 of 9 patients with poorly differentiated tumors. For more information, see the Cellular and Pathological Classification of Gastrointestinal Neuroendocrine Tumors section. Five- and 10-year crude survival rates were 96.1% and 73.9%, respectively, for type I tumors (not different from the general population) but only 33.3% and 22.2% for poorly differentiated gastric neuroendocrine tumors.[12][Level of evidence C2]

Sources: 12 · Cellular and Pathological Classification of Gastrointestinal Neuroendocrine Tumors · 12 · Level of evidence C2

Health professional

Treatment of Duodenal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Duodenal neuroendocrine (carcinoid) tumors are rare, and there is no consensus on the optimal extent of surgical treatment.[1] In a retrospective review of 24 patients with a pathological diagnosis of duodenal neuroendocrine tumor, most tumors (89%) measured smaller than 2 cm in diameter, and most (85%) were limited to the mucosa or submucosa. Lymph node metastases were identified in surgical specimens in 7 (54%) of 13 patients in whom lymph nodes were examined, including 2 patients with tumors smaller than 1 cm, which were limited to the submucosa. At a mean follow-up of 46 months, the disease-specific survival rate was 100%, and only 2 patients had recurrences in regional lymph nodes. No patient was reported to have distant metastases or the carcinoid syndrome.[1][Level of evidence C1] The authors concluded that although duodenal neuroendocrine tumors are indolent, the presence of regional lymph node metastases cannot be predicted reliably on the basis of tumor size or depth of invasion, and their impact on survival is unclear.

Sources: 1 · 1 · Level of evidence C1

In general, endoscopic excision of primary duodenal neuroendocrine tumors appears to be most appropriate for tumors smaller than 1 cm.[1] Duodenal neuroendocrine tumors smaller than 2 cm may be excised locally; for tumors between 1 cm and 2 cm, complete resection is ensured by operative full-thickness excision.[1,2] Follow-up endoscopy is indicated. Tumors larger than 1 cm may be difficult to remove completely endoscopically and should be evaluated with endoscopic ultrasonography before endoscopic resection is attempted because of their potential to invade beyond the submucosa.[3]

Sources: 1 · 1 · 2 · 3

Appropriate management of tumors larger than 2 cm can be problematic.[2] However, in general, these tumors can be treated with operative full-thickness excision and regional lymphadenectomy. Lymphadenectomy is performed even in the face of negative preoperative imaging because of the high rate of lymph node metastasis for these tumors.[1]

Sources: 2 · 1

In addition, some authors recommend that for tumors larger than 2 cm, a regional lymphadenectomy includes the lymph nodes in the following locations:

Posterior to the duodenum and pancreatic head and anterior to the inferior vena cava.

Posterolateral to the bile duct and portal vein.

Anterior to the common hepatic artery.[1,4]

Sources: 1 · 4

Regardless of the size of the primary tumor, abnormal lymph nodes detected on pretreatment imaging studies or at the time of surgery should be resected. Because little is known about the natural history of unresected, grossly evident lymph node metastases, nonoperative management might otherwise be supported. Node-positive patients should undergo continued radiographic surveillance regardless of the size of the primary tumor.[1]

Sources: 1

Ampullary and periampullary duodenal neuroendocrine tumors deserve special consideration because they differ clinically, histologically, and immunohistochemically from neuroendocrine tumors that occur elsewhere in the duodenum.[5] Although their rarity precludes the establishment of any definitive natural history, these tumors appear to behave unpredictably and might be viewed as a distinct category of carcinoid tumor when treatment options are being considered.[2] Compared with tumors in other duodenal sites, even small (<1 cm) ampullary and periampullary neuroendocrine tumors exhibit distinctly different aggressive behavior, and they may metastasize early.[5,6]

Sources: 5 · 2 · 5 · 6

Health professional

Treatment of Jejunal and Ileal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

At the time of diagnosis, 58% to 64% of patients with neuroendocrine (carcinoid) tumors of the small intestine have metastatic disease in the regional lymph nodes or the liver.[1] Early surgical treatment should include removal of the mesentery by wedge resection and resection of lymph node metastases surrounding the mesenteric artery and vein to preserve intestinal vascular supply and to limit the intestinal resection.[2] With grossly radical tumor resections, patients may remain symptom free for extended periods of time; however, because of the tenacity of neuroendocrine tumors, patients should undergo lifelong surveillance.

Sources: 1 · 2

Surgical treatment for advanced neuroendocrine tumors involves prophylactic removal of mesenteric metastases early on because later the disease may become impossible to manage surgically.[3] Repeat surgery may be necessary if mesenteric metastases are left during primary surgery or have progressed after primary surgery.[2] These operations are difficult because of fibrosis between regions of the intestine, and surgery may result in fistulation, intestinal devascularization, or creation of a short bowel.[3] The 5-year survival rate is approximately 50% for those with inoperable liver metastases and approximately 40% for those with inoperable liver and mesenteric metastases.[4,5]

Sources: 3 · 2 · 3 · 4 · 5

The effect of octreotide (long-acting repeatable, 30 mg intramuscularly every 28 days) on time to tumor progression in patients with metastatic midgut neuroendocrine tumors has been tested in a randomized placebo-controlled clinical trial.[6] Although the planned study accrual was 162 patients, because of slow accrual, it was stopped after 85 evaluable patients were enrolled. At an interim analysis, the median time to tumor progression was 14.3 months in the octreotide group versus 6 months in the placebo group (hazard ratio, 0.34; 95% confidence interval, 0.20–0.59; P < .0001). Quality of life was similar in both treatment groups. There was no difference in overall survival, but about three-quarters of the control group received octreotide at disease progression.[6][Level of evidence B1]

Sources: 6 · 6 · Level of evidence B1

Health professional

Treatment of Appendiceal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Approximately 90% of appendiceal neuroendocrine (carcinoid) tumors measure smaller than 1 cm and are not located in the appendiceal base. These tumors can be consistently cured by appendectomy.[1]

Sources: 1

Appendiceal neuroendocrine tumors larger than 2 cm require right-sided hemicolectomy and ileocecal lymphadenectomy because of the significant risk of metastasis.[1] For tumors measuring 1 to 2 cm, treatment is controversial, but hemicolectomy may be appropriate if there is invasion in the mesoappendix, if there is residual tumor in the resection margins, or in the presence of lymph node metastases. For same-size lesions confined to the appendiceal wall, appendectomy alone may carry a low risk for metastases. Acceptable indications for hemicolectomy may include operative specimens that show high proliferative activity (high Ki-67 index), high mitotic index, or signs of angioinvasion, but evidence is limited and histological parameters for risk evaluation in appendiceal neuroendocrine tumors measuring 1 cm to 2 cm requires definition.[1-3] Follow-up should be considered in patients for whom elevated serum chromogranin A may indicate the need for extended operation. Although survival is excellent with locoregional tumor, 10-year survival is approximately 30% with distant metastases.[1]

Sources: 1 · 1 · 3 · 1

Goblet cell carcinoid or adenocarcinoid is a rare variant of appendiceal neuroendocrine tumor with mixed endocrine and exocrine features.[1] Often presenting with a diffusely inflamed appendix and occurring in patients at a later age (~50 years), these tumors are aggressive, often with peritoneal and ovarian metastases, and occasionally appearing as mucinous adenocarcinoma.[2-4] They do not express somatostatin receptors and cannot be visualized by indium In 111-octreotide scintigraphy. Goblet cell carcinoids are treated with right-sided hemicolectomy and lymphadenectomy in combination with chemotherapy. For disseminated tumors, aggressive surgical reduction including peritonectomy and oophorectomy may be required.[1] Goblet cell carcinoids have a 10-year survival rate of approximately 60%.[2]

Sources: 1 · 2 · 4 · 1 · 2

Health professional

Treatment of Colonic Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Colonic neuroendocrine (carcinoid) tumors are often exophytic and large (>5 cm), but they rarely bleed. Only occasional right-sided lesions are positive with indium In 111-octreotide scintigraphy. Many of these tumors are aggressive with a high proliferation rate, and they often present with more liver metastases than regional lymph node metastases.[1] These tumors of the colon are treated similarly to adenocarcinoma of the colon.[2] Attempts to achieve radical resection by hemicolectomy or subtotal colectomy with lymphadenectomy should be made, but frequently only debulking is possible. The overall 5-year survival rate is approximately 40% and is slightly worse than the survival rate for patients with colon adenocarcinoma.[1]

Sources: 1 · 2 · 1

Health professional

Treatment of Rectal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

In general, rectal neuroendocrine (carcinoid) tumors often present as very small, isolated lesions.[1] The TNM (tumor, node, metastasis) system is used for rectal neuroendocrine tumors, but size appears to be one of the best estimates of recurrence. Rectal neuroendocrine tumors should be evaluated by endoscopic ultrasonography (EUS) or rectal magnetic resonance imaging (MRI). Tumors smaller than 1 cm can be safely removed by endoscopic excision.[2-5] Excised specimens should be examined histologically to exclude muscularis invasion.[2,6-8]. A report about the patients with rectal carcinoid tumors in the Surveillance, Epidemiology, and End Results (SEER) Program database demonstrated that the 5-year survival rate for patients with stage I carcinoid tumors was 97%.[9]

Sources: 1 · 2 · 5 · 2 · 6 · 8 · 9

For patients with tumors that are larger than 2 cm or that have invasion of the muscularis as seen by EUS or MRI, surgical resection with abdominoperineal resection (APR) or low anterior resection (LAR) is recommended because of the high rate of nodal metastases and risk of distant metastatic disease. In the report from the SEER database, patients with stage II or III rectal carcinoid tumors had 5-year survival rates of 84% and 20%, respectively.[9] In a report from the National Cancer Database, among 3,287 patients with rectal carcinoid tumors, the 5-year survival rates for patients with stage II or III disease were 87.3% and 35.5%, respectively.[10]

Sources: 9 · 10

There is considerable debate about whether local excision or rectal resection (i.e., APR or LAR) is needed for tumors that measure 1 cm to 2 cm. Although it may be possible to recognize tumors with particular atypia and high mitotic index before embarking on the more radical surgery, the presence of muscularis invasion or regional metastases generally supports rectal resection. In a multicenter series of 100 patients who underwent anterior resection for rectal carcinoid tumors, the rate of nodal metastases for patients with tumors between 1 cm and 2 cm was 31%.[11] In this series, tumor size larger than 1 cm and lymphovascular invasion were the two strongest predictors of lymph node metastases. In patients with distant metastases, prognosis is generally poor, with an overall 5-year survival rate of approximately 30%.[12]

Sources: 11 · 12

Health professional

Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

Although the definitive role of surgery in patients with metastatic disease has not been established, conservative resections of the intestine, mesenteric tumors, and fibrotic areas may improve symptoms and quality of life substantially in patients with metastatic hepatic, mesenteric, and peritoneal neuroendocrine (carcinoid) tumors. If the condition of the patient is such that surgery is not a greater risk than the disease, the primary tumor should be resected to prevent an emergency presentation with obstruction, perforation, or bleeding.[1] Despite common acceptance that resection of at least 90% of the tumor burden is required to achieve palliation, approximately 60% of patients with surgery alone will experience symptom recurrence; the 5-year survival rate is between 35% and 80%, depending on the experience of the surgical center.[2,3] Because treatment with somatostatin analogues can achieve similar rates of symptom relief with fewer adverse effects, in each patient the benefits of surgical treatment of gastrointestinal neuroendocrine tumors should be weighed carefully against the potential risks of an open exploration. Tumor debulking, however, may potentiate pharmacological therapy by decreasing the secretion of bioactive substances.[4]

Sources: 1 · 2 · 3 · 4

Management of hepatic metastases may include surgical resection; hepatic artery embolization; cryoablation and radiofrequency ablation; and orthotopic liver transplant. For more information, see the Treatment of Hepatic Metastases section. Cytoreductive surgery for hepatic metastases from gastrointestinal neuroendocrine tumors can be performed safely with minimal morbidity and mortality resulting in regression of symptoms and prolonged survival in most patients.[5] In one large review that included 120 patients with neuroendocrine tumors, a biochemical response rate of 96% and a 5-year survival rate of 61% were reported for patients whose hepatic metastases were resected surgically.[6][Level of evidence C2]

Sources: Treatment of Hepatic Metastases · 5 · 6 · Level of evidence C2

In the case of liver metastases, localization and resection of the primary tumor may be considered, even among patients in whom the primary neoplasm is asymptomatic. In a retrospective study involving 84 patients, 60 of whom had their primary neoplasm resected, the resected group had a greater median progression-free survival (PFS) of 56 months, compared with 25 months of PFS for the primary nonresected group (P < .001). Median survival time for the resected group was longer at 159 months when compared with 47 months for the nonresected group (P < .001).[7][Level of evidence C2]

Sources: 7 · Level of evidence C2

Although the response of neuroendocrine tumors to external-beam radiation therapy is very limited, palliative radiation therapy has some efficacy for bone and brain metastases and in the management of spinal cord metastases.[4]

Sources: 4

Treatment with single-agent chemotherapy or multiple-agent chemotherapy appears to be of little benefit in the management of gastrointestinal neuroendocrine tumors because no regimen has shown objective tumor response rates greater than 15%.[4]

Sources: 4

Treatment with radionuclides such as iodine I 131-metaiodobenzylguanidine and lutetium Lu 177-octreotate may be of benefit. For more information, see the Radionuclides section.

Sources: Radionuclides

Somatostatin analogues and interferon alfa are the primary agents used in the treatment of carcinoid syndrome. Management of the symptoms of carcinoid syndrome may also include dietary modification and the use of various antidiarrheal agents, antihistaminics for skin rashes, and theophylline or beta-2 adrenergic receptor agonists for bronchospasm. For more information, see the sections on Somatostatin Analogues, Interferons, and Symptomatic Therapy.

Sources: Somatostatin Analogues · Interferons · Symptomatic Therapy

Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional

Treatment of Recurrent Gastrointestinal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 9, 2025. Captured 2026-09-09.

The prognosis for any patient with progressive or recurrent disease is poor. Decisions about further treatment depend on many factors, including previous treatment, site of recurrence, and individual patient considerations. Attempts at re-resecting slow-growing tumors (e.g., repeat or multiple liver resections) are worthy of consideration after extensive evaluation, as further reduction of tumor volume may provide long-term palliation. Recurrence at any single site may also be potentially resectable. Clinical trials are appropriate and should be considered when possible.

Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

For patients · General Information About Gastrointestinal Neuroendocrine Tumors

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

Sources: prognosis

Where the tumor is in the gastrointestinal tract.

The size of the tumor.

Whether the cancer has spread from the stomach and intestines to other parts of the body, such as the liver or lymph nodes.

Whether the patient has carcinoid syndrome or has carcinoid heart syndrome.

Whether the cancer can be completely removed by surgery.

Sources: surgery

Whether the cancer is newly diagnosed or has recurred.

Sources: recurred

For patients · Stages of Gastrointestinal Neuroendocrine Tumors

The plan for cancer treatment depends on where the neuroendocrine tumor is found and whether it can be removed by surgery.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For many cancers it is important to know the stage of the cancer in order to plan treatment. However, the treatment of GI neuroendocrine tumors is not based on the stage of the cancer. Treatment depends mainly on whether the tumor can be removed by surgery and if the tumor has spread.

Sources: surgery

Treatment is based on whether the tumor:

Can be completely removed by surgery.

Has spread to other parts of the body.

Has come back after treatment. The tumor may come back in the stomach or intestines or in other parts of the body.

Sources: stomach · intestines

Has not gotten better with treatment.

For patients

Treatment Option Overview

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

There are different types of treatment for patients with gastrointestinal neuroendocrine tumors.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Hormone therapy

Treatment for carcinoid syndrome may also be needed.

New types of treatment are being tested in clinical trials.

New types of treatment are being tested in clinical trials.

Targeted therapy

Treatment for gastrointestinal neuroendocrine tumors may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with gastrointestinal neuroendocrine tumors.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Different types of treatment are available for patients with gastrointestinal neuroendocrine (GI) tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: gastrointestinal neuroendocrine (GI) tumors · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Treatment of GI neuroendocrine tumors usually includes surgery. One of the following surgical procedures may be used:

Sources: surgery

Endoscopic resection: Surgery to remove a small tumor that is on the inside lining of the GI tract. An endoscope is inserted through the mouth and passed through the esophagus to the stomach and sometimes, the duodenum. An endoscope is a thin, tube-like instrument with a light, a lens for viewing, and a tool for removing tumor tissue.

Sources: Endoscopic · resection · tumor · GI · endoscope · esophagus · stomach · duodenum · lens · tissue

Local excision: Surgery to remove the tumor and a small amount of normal tissue around it.

Sources: Local · excision

Resection: Surgery to remove part or all of the organ that contains cancer. Nearby lymph nodes may also be removed.

Sources: Resection · organ · lymph nodes

Cryosurgery: A treatment that uses an instrument to freeze and destroy the tumor. This type of treatment is also called cryotherapy. The doctor may use ultrasound to guide the instrument.

Sources: Cryosurgery · ultrasound

Radiofrequency ablation: The use of a special probe with tiny electrodes that release high-energy radio waves (similar to microwaves) that kill cancer cells. The probe may be inserted through the skin or through an incision (cut) in the abdomen.

Sources: Radiofrequency ablation · radio waves · cells · incision · abdomen

Liver transplant: Surgery to remove the whole liver and replace it with a healthy donated liver.

Sources: Liver · transplant · donated

Hepatic artery embolization: A procedure to embolize (block) the hepatic artery, which is the main blood vessel that brings blood into the liver. Blocking the flow of blood to the liver helps kill cancer cells growing there.

Sources: Hepatic artery · embolization · blood vessel · blood

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:

Sources: Radiation therapy · x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

Radiopharmaceutical therapy is a type of internal radiation therapy. Radiation is given to the tumor using a drug that has a radioactive substance, such as iodine I 131, attached to it. The radioactive substance kills the tumor cells.

Sources: Radiopharmaceutical · drug

External and internal radiation therapy are used to treat GI neuroendocrine tumors that have spread to other parts of the body.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy).

Sources: Chemotherapy · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · regional chemotherapy

Chemoembolization of the hepatic artery is a type of regional chemotherapy that may be used to treat a GI neuroendocrine tumor that has spread to the liver. The anticancer drug is injected into the hepatic artery through a catheter (thin tube). The drug is mixed with a substance that embolizes (blocks) the artery and cuts off blood flow to the tumor. Most of the anticancer drug is trapped near the tumor and only a small amount of the drug reaches other parts of the body. The blockage may be temporary or permanent, depending on the substance used to block the artery. The tumor is prevented from getting the oxygen and nutrients it needs to grow. The liver continues to receive blood from the hepatic portal vein, which carries blood from the stomach and intestine.

Sources: Chemoembolization · oxygen · nutrients · hepatic portal vein · stomach · intestine

The way the chemotherapy is given depends on the type and stage of the cancer being treated.

Sources: stage

For patients · Treatment Option Overview / The following types of treatment are used:

Hormone therapy

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Hormone therapy with a somatostatin analog is a treatment that stops extra hormones from being made. GI neuroendocrine tumors are treated with octreotide or lanreotide which are injected under the skin or into the muscle. Octreotide and lanreotide may also have a small effect on stopping tumor growth.

Sources: Hormone therapy · analog · hormones · octreotide

For patients · Treatment Option Overview

Treatment for carcinoid syndrome may also be needed.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Treatment of carcinoid syndrome may include:

Sources: carcinoid syndrome

Hormone therapy with a somatostatin analog stops extra hormones from being made. Carcinoid syndrome is treated with octreotide or lanreotide to lessen flushing and diarrhea. Octreotide and lanreotide may also help slow tumor growth.

Sources: diarrhea

Interferon therapy stimulates the body's immune system to work better and lessens flushing and diarrhea. Interferon may also help slow tumor growth.

Sources: Interferon · immune system

Taking medicine for diarrhea.

Sources: medicine

Taking medicine for skin rashes.

Taking medicine to breathe easier.

Taking medicine before having anesthesia for a medical procedure.

Sources: anesthesia

Other ways to help treat carcinoid syndrome include avoiding things that cause flushing or difficulty breathing such as alcohol, nuts, certain cheeses and foods with capsaicin, such as chili peppers. Avoiding stressful situations and certain types of physical activity can also help treat carcinoid syndrome.

Sources: alcohol · capsaicin · stressful

For some patients with carcinoid heart syndrome, a heart valve replacement may be done.

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Targeted therapy

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. Several types of targeted therapy are being studied in the treatment of GI neuroendocrine tumors.

Sources: Targeted therapy

For patients · Treatment Option Overview

Treatment for gastrointestinal neuroendocrine tumors may cause side effects.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Neuroendocrine Tumors in the Stomach

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of gastrointestinal (GI) neuroendocrine tumors in the stomach may include:

Sources: gastrointestinal (GI) neuroendocrine tumors · stomach

Endoscopic surgery (resection) for small tumors.

Sources: Endoscopic · surgery · resection · tumors

Surgery (resection) to remove part or all of the stomach. Nearby lymph nodes for larger tumors, tumors that grow deep into the stomach wall, or tumors that are growing and spreading quickly may also be removed.

Sources: lymph nodes

For patients with GI neuroendocrine tumors in the stomach and MEN1 syndrome, treatment may also include:

Sources: MEN1 syndrome

Surgery (resection) to remove tumors in the duodenum (first part of the small intestine, that connects to the stomach).

Sources: duodenum · small intestine

Hormone therapy.

Sources: Hormone therapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Neuroendocrine Tumors in the Small Intestine

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

It is not clear what the best treatment is for gastrointestinal (GI) neuroendocrine tumors in the duodenum (first part of the small intestine, that connects to the stomach). Treatment may include:

Sources: gastrointestinal (GI) neuroendocrine tumors · duodenum · small intestine · stomach

Endoscopic surgery (resection) for small tumors.

Sources: Endoscopic · surgery · resection · tumors

Surgery (local excision) to remove slightly larger tumors.

Sources: local · excision

Surgery (resection) to remove the tumor and nearby lymph nodes.

Sources: lymph nodes

Treatment of GI neuroendocrine tumors in the jejunum (middle part of the small intestine) and ileum (last part of the small intestine, that connects to the colon) may include:

Sources: jejunum · ileum · colon

Surgery (resection) to remove the tumor and the membrane that connects the intestines to the back of the abdominal wall. Nearby lymph nodes are also removed.

Sources: membrane · intestines · abdominal · lymph nodes

A second surgery to remove the membrane that connects the intestines to the back of the abdominal wall, if any tumor remains or the tumor continues to grow.

Hormone therapy.

Sources: Hormone therapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Neuroendocrine Tumors in the Appendix

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of gastrointestinal (GI) neuroendocrine tumors in the appendix may include:

Sources: gastrointestinal (GI) neuroendocrine tumors · appendix

Surgery (resection) to remove the appendix.

Sources: Surgery · resection

Surgery (resection) to remove the right side of the colon including the appendix. Nearby lymph nodes are also removed.

Sources: colon · lymph nodes

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Neuroendocrine Tumors in the Colon

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of gastrointestinal (GI) neuroendocrine tumors in the colon may include:

Sources: gastrointestinal (GI) neuroendocrine tumors · colon

Surgery (resection) to remove part of the colon and nearby lymph nodes, in order to remove as much of the cancer as possible.

Sources: Surgery · resection · lymph nodes · cancer

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Neuroendocrine Tumors in the Rectum

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of gastrointestinal (GI) neuroendocrine tumors in the rectum may include:

Sources: gastrointestinal (GI) neuroendocrine tumors · rectum

Endoscopic surgery (resection) for tumors that are smaller than 1 centimeter.

Sources: Endoscopic · surgery · resection · tumors · centimeter

Surgery (resection) for tumors that are larger than 2 centimeters or that have spread to the muscle layer of the rectal wall. This may be either:

Sources: rectal

Surgery (resection) for tumors that are larger than 2 centimeters or that have spread to the muscle layer of the rectal wall. This may be either:

surgery to remove part of the rectum; or

surgery to remove the anus, the rectum, and part of the colon through an incision made in the abdomen.

Sources: anus · colon · incision · abdomen

It is not clear what the best treatment is for tumors that are 1 to 2 centimeters. Treatment may include:

Endoscopic surgery (resection).

Surgery (resection) to remove part of the rectum.

Surgery (resection) to remove the anus, the rectum, and part of the colon through an incision made in the abdomen.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Distant metastases

Treatment of distant metastases of gastrointestinal (GI) neuroendocrine tumors is usually palliative therapy to relieve symptoms and improve quality of life. Treatment may include:

Sources: distant metastases · gastrointestinal (GI) neuroendocrine tumors · palliative therapy · symptoms · quality of life

Surgery (resection) to remove as much of the tumor as possible.

Sources: Surgery · resection · tumor

Hormone therapy.

Sources: Hormone therapy

Radiopharmaceutical therapy.

Sources: Radiopharmaceutical · therapy

External radiation therapy for cancer that has spread to the bone, brain, or spinal cord.

Sources: External radiation therapy · cancer · brain · spinal cord

A clinical trial of a new treatment.

Sources: clinical trial

Liver metastases

Treatment of cancer that has spread to the liver may include:

Sources: liver

Surgery (local excision) to remove the tumor from the liver.

Sources: local · excision

Hepatic artery embolization.

Sources: Hepatic artery · embolization

Cryosurgery.

Sources: Cryosurgery

Radiofrequency ablation.

Sources: Radiofrequency ablation

Liver transplant.

Sources: transplant

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Gastrointestinal Neuroendocrine Tumors

Source: Gastrointestinal Neuroendocrine Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: February 20, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of recurrent gastrointestinal (GI) neuroendocrine tumors may include:

Sources: recurrent · gastrointestinal (GI) neuroendocrine tumors

Surgery (local excision) to remove part or all of the tumor.

Sources: Surgery · local · excision · tumor

A clinical trial of a new treatment.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

NCT00412061 · COMPLETED · phase3

Carcinoid Tumor, Malignant Carcinoid Syndrome

ClinicalTrials.gov record

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

NCT00510068 · COMPLETED · phase3

Advanced Neuroendocrine Tumors of Pancreatic Origin

ClinicalTrials.gov record

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320 · ACTIVE NOT RECRUITING · phase3

Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced...

ClinicalTrials.gov record

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

NCT01253161 · COMPLETED · phase2

Neuroendocrine Tumors, Carcinoid Tumors

ClinicalTrials.gov record

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

NCT01869725 · COMPLETED · phase2

Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor, Somatostatinoma

ClinicalTrials.gov record

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

NCT02299089 · COMPLETED · phase2

Acromegaly, Neuroendocrine Tumors

ClinicalTrials.gov record

Open-Label Surufatinib in European Patients With NET

NCT04579679 · TERMINATED · phase2

Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET

ClinicalTrials.gov record

Disease and treatment settings

BYNFEZIA Pen: metastatic carcinoid

Disease and treatment setting

1.2 Carcinoid Tumors BYNFEZIA PEN is indicated for treat ment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

Gastrointestinal Neuroendocrine Tumors

Disease and treatment setting

Gastrointestinal Neuroendocrine Tumors

metastatic Gastrointestinal Neuroendocrine Tumors

Disease and treatment setting

Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors

Neuroendocrine Tumor

Disease and treatment setting

Neuroendocrine Tumor

recurrent Gastrointestinal Neuroendocrine Tumors

Disease and treatment setting

Treatment of Recurrent Gastrointestinal Neuroendocrine Tumors

Sandostatin LAR Depot: metastatic carcinoid

Disease and treatment setting

SANDOSTATIN LAR DEPOT is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for: Acromegaly ( 1.1 ) Severe diarrhea/flushing episodes associated...

Sandostatin: metastatic carcinoid

Disease and treatment setting

1.2 Carcinoid Tumors Sandostatin Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

Drug labels

Afinitor

Label date 2026-06-01

AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or...

DailyMed label

Detectnet

Label date 2025-01-31

Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. Detectnet is a radioactive diagnostic agent indicated for use with...

DailyMed label

Ga-68-DOTATOC

Label date 2021-12-08

Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. Ga 68 DOTATOC Injection is a...

DailyMed label

Lanreotide Acetate

Label date 2024-09-01

Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult...

DailyMed label

Lutathera

Label date 2026-01-15

LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

DailyMed label

NETSPOT

Label date 2026-07-06

NETSPOT, after radiolabeling with gallium-68, is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. NETSPOT, after...

DailyMed label

OCTREOSCAN

Label date 2022-02-21

INDICATIONS AND USAGE Octreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.

DailyMed label

Sandostatin

Label date 2026-07-22

Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or...

DailyMed label

SOMATULINE DEPOT

Label date 2024-10-11

SOMATULINE DEPOT is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult...

DailyMed label